“The formation of Dogwood Therapeutics last month represents a transformational expansion of our pipeline with the addition of Halneuron ®, a non-opioid, novel NaV 1.7 modulator to treat neuropathic ...
As previously disclosed in a press release on November 13, 2023, 180 Degree Capital’s Board of Directors has set two measurement periods of January 1, 2024 to December 31, 2024, and January 1, 2025 to ...